Drug Trial Radar · NCT05013229
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
679
Actual
Start
Nov 30, 2021
Primary completion
Nov 14, 2023
Study completion Nov 14, 2023
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Aug 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine taken daily with insulin aspart in people with type 2 diabetes.The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken with insulin aspart. Participants will either get IcoSema or insulin glargine taken with insulin aspart. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe insulin glargine and insulin aspart in many countries. Participants will get IcoSema or insulin glargine together with insulin aspart. Participants must inject IcoSema once a week or inject insulin glargine once daily and insulin aspart 2-4 times a day. Participants will inject the medicines with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will be asked to wear a sensor that measures participants blood sugar level all the time during an 8 week period at the beginning of the study and a 4 week period at the end of the study. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
Conditions
- Diabetes Mellitus, Type 2
Interventions
IcoSemaDrug
Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.
Insulin glargineDrug
Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
insulin aspartDrug
Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: From baseline week 0 (V2) to week 52 (V54)
Locations
182 sites in 14 countries. Site status is shown where the registry gives one.
Lakeview Clinical Research, LLC
Guntersville, Alabama
Valley Research
Fresno, California
Scripps Wht Diab Inst La Jolla
La Jolla, California
Torrance Clin Res Inst, Inc.
Lomita, California
Downtown LA Res Ctr. Inc.
Los Angeles, California
San Diego Family Care
San Diego, California
NorCal Endocrinology and Internal Medicine
San Ramon, California
Creekside Endocrine Associates
Denver, Colorado
Clinical Res Of W Florida Inc
Clearwater, Florida
Northeast Research Institute
Fleming Island, Florida
Sweet Hope Research Specialty
Hialeah, Florida
E Coast Inst for Rsrch LLC_Jacksonville
Jacksonville, Florida
Northeast Res Inst. Inc.
Jacksonville, Florida
East Coast Institute for Research, LLC
Jacksonville, Florida
South Broward Research LLC
Miramar, Florida
Adult Medicine of Lake County, Inc.
Mt. Dora, Florida
Renstar Medical Research
Ocala, Florida
Florida Inst For Clin Res
Orlando, Florida
Metabolic Research Institute Inc
West Palm Beach, Florida
Physicians Research Assoc. LLC
Lawrenceville, Georgia
Endo Res Solutions Inc
Roswell, Georgia
East West Med Res Inst
Honolulu, Hawaii
Saltzer Medical Group Research
Nampa, Idaho
Endeavor Health
Skokie, Illinois
Iowa Diab & Endo Res Center
West Des Moines, Iowa
Cotton-O'Neil Diab & Endo Ctr
Topeka, Kansas
The Research Group of Lexington LLC
Lexington, Kentucky
New Orleans Center for Clinical Research
New Orleans, Louisiana
MedStar Hlth Res Institute
Hyattsville, Maryland
ActivMed Practice & Research LLC
Methuen, Massachusetts
Northern Pines Hlth Ctr, PC
Buckley, Michigan
StudyMetrix Research LLC
City of Saint Peters, Missouri
Univ of Nebraska Medical CTR
Omaha, Nebraska
Palm Research Center Inc-Vegas
Las Vegas, Nevada
Southern NH Diabetes and Endocrinology
Nashua, New Hampshire
John J Shelmet, MD
Lawrenceville, New Jersey
Mid Hudson Med Res-New Windsor
New Windsor, New York
DiGiovanna Institute for Medical Education & Research
North Massapequa, New York
Southgate Medical Group, LLP
West Seneca, New York
Physicians East Endocrinology
Greenville, North Carolina
Showing 40 of 182 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.